[go: up one dir, main page]

DK2134847T3 - Grisemodel for aterosklerose - Google Patents

Grisemodel for aterosklerose Download PDF

Info

Publication number
DK2134847T3
DK2134847T3 DK08715609.7T DK08715609T DK2134847T3 DK 2134847 T3 DK2134847 T3 DK 2134847T3 DK 08715609 T DK08715609 T DK 08715609T DK 2134847 T3 DK2134847 T3 DK 2134847T3
Authority
DK
Denmark
Prior art keywords
pig
gene
oocytes
cell
mini
Prior art date
Application number
DK08715609.7T
Other languages
English (en)
Inventor
Jacob Giehm Mikkelsen
Erling Falk
Thomas Juhl Corydon
Jacob Bentzon Fog
Peter Michael Kragh
Charlotte Brandt Sørensen
Lars Axel Bolund
Original Assignee
Univ Aarhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus filed Critical Univ Aarhus
Application granted granted Critical
Publication of DK2134847T3 publication Critical patent/DK2134847T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8778—Swine embryos
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (8)

1. Genetisk modificeret minigris som model for undersøgelse af aterosklerose, hvor grisemodellen udtrykker mindst én fænotype, som er associeret med aterosklerose, og omfatter mindst én mutation i i. det endogene ApoE-gen og/eller ii. det endogene LDL-receptorgen, hvor den mindst ene fænotype er hypercholesterolæmi.
2. Modificeret gris ifølge krav 1, hvor minigrisen er valgt fra gruppen bestående af Goettingen, Yucatan, Bama Xiang Zhu, Wuzhishan og Xi Shuang Banna, herunder en hvilken som helst kombination deraf.
3. Genetisk modificeret porcin blastocyst, som stammer fra den genetisk modificerede grisemodel som defineret i krav 1.
4. Genetisk modificeret porcint embryo, som stammer fra den genetisk modificerede grisemodel som defineret i krav 1.
5. Genetisk modificeret porcint føtus, som stammer fra den genetisk modificerede grisemodel som defineret i krav 1.
6. Genetisk modificeret porcin donorcelle og/eller cellekerne, som stammer fra den genetisk modificerede grisemodel som defineret i krav 1.
7. Fremgangsmåde til evaluering af virkningen af en terapeutisk behandling af aterosklerose, hvilken fremgangsmåde omfatter følgende trin i) der tilvejebringes en grisemodel ifølge krav 1, ii) den virkning, der observeres på grisemodellen, som er behandlet med et farmaceutisk præparat, evalueres.
8. Fremgangsmåde til screening af effektiviteten af et farmaceutisk præparat, hvilken fremgangsmåde omfatter følgende trin i) der tilvejebringes en grisemodel ifølge krav 1, ii) den genetiske determinant udtrykkes i grisemodellen, og det bevirkes, at fænotypen for sygdommen kommer frem, iii) den eventuelle virkning på grisemodellen, som er behandlet med det farmaceutiske præparat, evalueres.
DK08715609.7T 2007-03-07 2008-03-06 Grisemodel for aterosklerose DK2134847T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700348 2007-03-07
PCT/DK2008/050055 WO2008106982A2 (en) 2007-03-07 2008-03-06 Pig model for atherosclerosis

Publications (1)

Publication Number Publication Date
DK2134847T3 true DK2134847T3 (da) 2015-10-05

Family

ID=39596393

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08715609.7T DK2134847T3 (da) 2007-03-07 2008-03-06 Grisemodel for aterosklerose

Country Status (6)

Country Link
US (1) US8546643B2 (da)
EP (1) EP2134847B1 (da)
CA (1) CA2716990A1 (da)
DK (1) DK2134847T3 (da)
ES (1) ES2547015T3 (da)
WO (1) WO2008106982A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8912386B2 (en) 2007-03-28 2014-12-16 University Of Iowa Research Foundation Transgenic pig model of cystic fibrosis
EP2141985B1 (en) * 2007-03-28 2018-10-17 University of Iowa Research Foundation Transgenic pig models of cystic fibrosis
US8618352B2 (en) 2007-03-28 2013-12-31 University Of Iowa Research Foundation Transgenic porcine models of cystic fibrosis
GB0922377D0 (en) * 2009-12-22 2010-02-03 Arab Gulf University The Mutant LDL receptor
BR112012020257A8 (pt) * 2010-02-11 2018-02-14 Recombinetics Inc métodos e aparelhos para produzir artiodátilos transgênicos
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
JP6172699B2 (ja) * 2011-12-08 2017-08-02 プライムテック株式会社 高脂血症モデルブタ
US10568974B2 (en) * 2012-02-07 2020-02-25 Exemplar Genetics Llc Animal models of atherosclerosis
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058078B2 (en) 2012-07-31 2018-08-28 Recombinetics, Inc. Production of FMDV-resistant livestock by allele substitution
RU2524127C1 (ru) * 2013-05-14 2014-07-27 Государственное научное учреждение Всероссийский научно-исследовательский институт мясной промышленности им. В.М. Горбатова Российской академии сельскохозяйственных наук Способ моделирования атеросклероза
AP2016009207A0 (en) 2013-10-25 2016-05-31 Livestock Improvement Corp Ltd Genetic markers and uses therefor
US9428767B2 (en) * 2014-04-09 2016-08-30 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression
US10927384B2 (en) 2014-04-09 2021-02-23 Dna Twopointo Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
DK3359671T3 (da) 2015-10-08 2021-09-20 Dna Twopointo Inc Dna-vektorer, transposoner og transposaser til eukaryot genommodifikation
AU2018314257B2 (en) 2017-08-11 2025-03-27 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life
EP3787543A4 (en) 2018-05-02 2022-01-19 Augmedics Ltd. REGISTRATION OF A REFERENCE MARK FOR AN AUGMENTED REALITY SYSTEM
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
WO2024057210A1 (en) 2022-09-13 2024-03-21 Augmedics Ltd. Augmented reality eyewear for image-guided medical intervention

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4984697A (en) * 1996-10-11 1998-05-11 The Texas A & M University System Methods for the generation of primordial germ cells and transgenic animal species
US6498285B1 (en) * 1997-08-06 2002-12-24 Alexion Pharmaceuticals, Inc. Methods for producing transgenic pigs by microinjecting a blastomere
KR100417566B1 (ko) 1999-11-19 2004-02-05 한국생명공학연구원 체세포 핵치환 복제수정란의 대량생산방법
JP2003225089A (ja) 2002-02-04 2003-08-12 National Institute Of Agrobiological Sciences ブタｒａｇ−１遺伝子およびその利用
US20030208785A1 (en) * 2002-05-06 2003-11-06 Animal Technology Institute Taiwan Transgenic pig containing heat shock protein 70 transgene
EP1471152A1 (en) * 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
KR100479704B1 (ko) 2003-10-08 2005-03-31 (주)엠젠바이오 녹색 형광단백질을 발현하는 형질전환 돼지의 제조 방법
GB0507983D0 (en) * 2005-04-20 2005-05-25 Univ Cambridge Tech Apoptosis model
US8513486B2 (en) * 2005-09-08 2013-08-20 Aarhus Universitet Cell nuclear transfer
CA2715852A1 (en) * 2007-03-07 2008-09-12 Aarhus Universitet A pig whose genome comprises a site-specific, heterologous recombination site

Also Published As

Publication number Publication date
US20100138939A1 (en) 2010-06-03
WO2008106982A2 (en) 2008-09-12
US8546643B2 (en) 2013-10-01
WO2008106982A3 (en) 2008-12-31
CA2716990A1 (en) 2008-09-12
EP2134847A2 (en) 2009-12-23
EP2134847B1 (en) 2015-06-24
ES2547015T3 (es) 2015-09-30

Similar Documents

Publication Publication Date Title
DK2134847T3 (da) Grisemodel for aterosklerose
US20060294610A1 (en) Alpha1-3 galactosyltransferase gene and promoter
JP2009502120A (ja) ブタからヒトへのレトロエレメント移入を減少するためのシトシン脱アミノ酵素の使用法
CA2308121A1 (en) Mammals lacking expression of osteoprotegerin
EP1870472B1 (en) Model animal of Alzheimer's disease and use thereof
DK2134846T3 (da) Transgent svin som model for Alzheimers sygdom
Viglietta et al. The generation of transgenic rabbits
CA2715852A1 (en) A pig whose genome comprises a site-specific, heterologous recombination site
Samiec et al. The possibilities of practical application of transgenic mammalian species generated by somatic cell cloning in pharmacology, veterinary medicine and xenotransplantology
US10729112B2 (en) Pig model for diabetes
JP4845073B2 (ja) 再構築受精卵の作製方法及びそれを用いたトランスジェニック胚の作製方法
CN102016029B (zh) 将外源基因导入灵长类动物的早期胚胎的方法和包含该方法的生产转基因灵长类动物的方法
US20090214482A1 (en) Transgenic Mammals Expressing Human Preproinsulin
KR20110117841A (ko) Ｐｅｐｃｋ 과발현 형질전환 복제 개과 동물 및 이의 생산방법
Lois Generation of transgenic animals using lentiviral vectors
CN116322587A (zh) 用于异种移植的基因修饰
KR20120089067A (ko) 목적유전자를 조건적으로 발현하는 복제된 개과동물의 생산방법
JP2004135657A (ja) ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
Gavin et al. Transgenic cloned goats and cows for the production of therapeutic proteins
Robl et al. Embryonic Stem Cell Chimeras and Somatic Cell Nuclear Transplantation for Production of Transgenic Cattle
WO2002073187A1 (en) Method for generating replacement cells and/or tissues
Van der Meer Transgenesis and animal welfare
WO2004111252A1 (en) Efficient production of transgenic animals